Non-obese adult onset diabetes with oral hypoglycemic agent failure: Islet cell autoantibodies or reversible beta cell refractoriness?

Brazilian Journal of Medical and Biological Research

Volumn 36, Issue 10, 2003, Pages 1301-1309

  Sa J R ^a   Silva, R C ^a   Nasri, F ^a   Aguade, L C M ^a   Velloso, L ^a   Chacra, A R ^a   Dib, S A ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Beta cell function; Insulin sensitivity; Islet cell antibodies; Non insulin dependent diabete mellitus; Non obese diabetes mellitus; Oral hypoglycemic agent failure

Indexed keywords

AUTOANTIBODY; C PEPTIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PANCREAS ISLET CELL ANTIBODY; SULFONYLUREA DERIVATIVE;

ADULT; ANTIBODY DETECTION; ARTICLE; BRAZIL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DESENSITIZATION; DIET RESTRICTION; DIET THERAPY; DRUG RESPONSE; ETHNOLOGY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; INSULIN SENSITIVITY; INSULIN TREATMENT; LEAN BODY WEIGHT; MALE; MATURITY ONSET DIABETES MELLITUS; MAXIMUM PERMISSIBLE DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; REST; STATISTICAL MODEL; TREATMENT FAILURE;

EID: 0142210404     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2003001000005     Document Type: Article

References (40)

1. Simó R & Hernandez C (2002). Tratamiento de la diabetes mellitus: objetivos generales y manejo en la práctica clínica. Revista Española de Cardiología, 55: 845-860.
2. Matthews DR, Cull CA, Stratton IM, Holman RR & Turner RC (1998). UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabetic Medicine, 15: 297-303.
3. Irvine WJ, McCallum CJ, Gray RS & Duncan LJ (1977). Clinical and pathogenic significance of pancreatic islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet, 1: 1025-1027.
4. Kobayashi T, Itoh T, Kosaka K, Sato K & Tsuji K (1987). Time course of islet cell antibodies and β-cell function in non-insulin dependent stage of type I diabetes. Diabetes, 36: 510-517.
5. Robertson RP, Harmon J, Tran PO, Tanaka Y & Takahashi H (2003). Glucose toxicity in β-cells: Type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes, 52: 581-587.
6. Seissler J, de Sonnaville JJJ, Morgenthaler NG, Steinbrenner H, Glawe D, Khoo-Morgenthaler UY, Lan MS, Nolkins AL, Heine RJ & Scherbaum WA (1998). Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia, 41: 891-897.
7. Tuomi T, Groop LC, Zimmet P, Rowley MJ, Knowles W & Mackay IR (1993). Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes in adults with a non-insulin-dependent onset of disease. Diabetes, 42: 359-362.
8. Zimmet P, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M & Lang DA (1994). Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabetic Medicine, 11: 299-303.
9. Evans JL, Goldfine ID, Madduk BA & Grodsky GM (2002). Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocrine Reviews, 23: 599-622.
10. De Fronzo R & Simonson DC (1992). Glucose toxicity. In: Mazzaferri EL (Editor), Advances in Endocrinology and Metabolism/3. Mosby-Year Book Inc., Chicago, IL, USA, 1-41.
11. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997). Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 20: 1183-1197.
12. Seltzer HS (1980). Efficacy and safety of oral hypoglycemic agents. Annual Review of Medicine, 31: 261-272.
13. Sá JR, Russo EMK, Miranda WL, Vieira JGH, Santiago RCM, Chacra AR & Lourenço DM (1987). Comparação entre os métodos de cromatrografia de troca iônica e cromatografia de afinidade para a dosagem de hemoglobina glicosilada (HbA1c). Arquivos Brasileiros de Endocrinologia e Metabolismo, 31: 1-3.
14. Heding LG & Munkgaard RS (1975). Human C peptide in normal and diabetic subjects. Diabetologia, 11: 201-206.
15. Dib SA, Colmann PG, Dotta F & Eisenbarth GS (1987). Expression of cytoplasmic islet cell antigens by rat pancreas. Diabetes, 36: 982-985.
16. Velloso LA, Kampe O, Hallberg A, Christmanson L, Betsholtz C & Karlsson A (1993). Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type I diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. Journal of Clinical Investigation, 91: 2084-2090.
17. Levy JC, Matthews DR & Hermans MP (1998). Correct Homeostasis Model Assessment (HOMA) evaluation uses the computer program. Diabetes Care, 21: 2191-2192.
18. Zimmet P, Turner R, McCarty D, Merril R & Mackay I (1999). Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care, 22: B59-B64.
19. Laakso M & Pyorala K (1985). Age of onset and type of diabetes. Diabetes Care, 8: 114-117.
20. Leahy JL, Bonner-Weir S & Weir G (1992). Beta cell dysfunction induced by chronic hyperglycaemia. Diabetes Care, 15: 442-445.
21. Humphrey ARG, McCarty DJ, Mackay IR, Rowley MJ, Dwyer T & Zimmet P (1998). Autoantibodies to glutamic acid decarboxylase and phenotypic features associated with early insulin treatment in individuals with adult-onset diabetes mellitus. Diabetic Medicine, 15: 113-119.
22. Melton III LJ, Palumbo PJ & Chu CP (1983). Incidence of diabetes mellitus by clinical type. Diabetes Care, 6: 75-86.
23. Hother-Nielsen O, Faber O, Sorensen NS & Beck-Nielsen H (1988). Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care, 11: 531-537.
24. Maldonado M, Hampe C, Iyer D, Rajan A, Hammerle L, Lermark A & Balasubramanyam A (2001). Clinical and biologic heterogeneity of diabetes presenting with ketoacidosis. Diabetes, 50 (Suppl 2): A262 (Abstract).
25. Torella R, Salvatore T, Cozzolino D, Giunta R, Quatraro A & Giugliano D (1991). Restoration of sensitivity to sulfonylurea after strict glycemic control with insulin in non-obese type 2 diabetic subjects. Diabetes and Metabolism, 17: 443-447.
26. Hsich SD, Kanazawa Y & Akanuma Y (1985). Serum free C-peptide response to oral glucose loading as a parameter for the monitoring of pancreatic B-cell function in diabetic patients. Diabetes Research and Clinical Practice, 1: 109-114.
27. França AP, Maltez DL, Reis AF, Tavares E, Shiota D, Nasri F, Moisés RCS, Sá JR & Dib SA (1997). Peptídeo-C de jejum na classificação dos diferentes tipos de diabetes mellitus. Arquivos Brasileiros de Endocrinologia e Metabolismo, 41: 26 (Abstract).
28. Laakso M, Ronnemaa T, Sarlund HH, Pyorala K & Kallio V (1989). Factors associated with fasting and post-glucagon plasma C-peptide levels in middle-aged insulin-treated diabetic patients. Diabetes Care, 12: 83-88.
29. The DCCT Research Group (1986). The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for feasibility phase. Diabetes, 35: 530-545.
30. Peng YS & Juang JH (1998). Effects of insulin therapy on noninsulin-dependent diabetics with secondary agent failure. Changgeng Yi Xue Za Zhi, 21: 271-276.
31. Scheen A, Castillo MS & Lefebvre P (1996). Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes and Metabolism, 22: 397-406.
32. Taverna MJ, Pacher N, Bruzzo G, Slama G & Selam JL (2001). Beta-cell function evaluated by HOMA as a predictor of secondary sulphonylurea failure in type 2 diabetes. Diabetic Medicine, 18: 584-588.
33. Matthews DR, Hosker JP, Rudenski AS, Treacher DF & Turner RC (1985). Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28: 412-419.
34. Yki-Jarvinen H, Esko N, Eero H & Taskinni MR (1988). Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. American Journal of Medicine, 84: 185-192.
35. Karvestedt L, Andersson G, Efendic S, Clauson P & Grill V (1998). Improvement of β-cell function by intensive insulin treatment is rapidly induced and rapidly lost. EASD'98, 34th Annual Meeting, Barcelona, Spain, September 8-12, Abstract 962.
36. Jennings AM, Spencer KM, Wilson RM, Botazzo GF & Ward JD (1989). Islet cell antibodies and insulin autoantibodies in patients treated with oral hypoglycaemic agents. Diabetic Medicine, 6: 434-439.
37. Groop LC, Botazzo GF & Doniach D (1986). Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis. Diabetes, 35: 237-241.
38. Niskansen LK, Tuomi T, Karjalainen J, Groop LC & Uusitupa MIJ (1995). GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care, 18: 1557-1565.
39. Hagopian WA, Karlsen AE, Gottsater A, Landin-Olsson M, Grubin CE, Sundkvist G, Pedersen JS, Boel E, Dyberg T & Lernmark Å (1993). Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type 1. Journal of Clinical Investigation, 91: 368-374.
40. Bjork E, Kampe O, Karlsson FA, Pipeleers DG, Andersson A, Hellerstrom C & Eizirik DL (1992). Glucose regulation of the autoantigen GAD65 in human pancreatic islets. Journal of Clinical Endocrinology and Metabolism, 75: 1574-1576.